Extended Data Table 3 Immune-mediated adverse events by categorya

From: Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial

  1. aThe safety population included all patients who had received at least one dose of a trial drug. Listed are events that were reported between the first dose and 135 days after the last dose. Includes patients with immune-mediated adverse events where immune modulating medication was initiated by category. The severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
Back to article page